multiple or single - hard to establish however it would seem to indicate the interest is strong on and offshore
no surprise really - pharma product valuations gain traction and generate interest when phase 3 interim trial data is is in the air - they are a recognised driver of valuation creation at this point in their development progression
perhaps more so here with Avecho, as the 'therapy area' being addressed (insomnia and anxiety) has limited effective low impact treatment options available creating a significant 'interest' driver / the value of the trail design in this instance should not be overlooked imo In addition the companies work to develop TPM and establish its credentials as a successful bioavailability / absorption mechanism - both topically and orally and to also gain stand alone regulatory approval should it prove its worth in the phase 3 insomnia trial outcome may also prove to be a significant 'interim' valuation driver for any potential agreement going forward.
there is value holding here atm imo though the risk is high
'early' - agree with you most likely Q1
we'll see red or black
AVE Price at posting:
0.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)